# Genome edited iPS cell-derived macrophages as a novel lung cell therapy > **NIH NIH R01** · CINCINNATI CHILDRENS HOSP MED CTR · 2020 · $390,000 ## Abstract PROJECT SUMMARY / ABSTRACT Hereditary pulmonary alveolar proteinosis (hPAP), a disease we previously identified, is characterized by pulmonary surfactant accumulation and respiratory failure due to alveolar macrophage (MФ) dysfunction caused by mutations in the genes encoding GM-CSF receptor α or β (CSF2RA, CSF2RB, respectively), for which no specific pharmacotherapy currently exists. We also showed that pulmonary GM-CSF is a critical determinate of the alveolar MФ phenotype and developed a novel cell transplantation approach – pulmonary macrophage transplantation (PMT) with extraordinary therapeutic efficacy in an authentic preclinical animal model of hPAP (Csf2rb-/- mice). Our long term goal is to develop an effective definitive therapy for hPAP that is acceptable for use in children, in whom hPAP most commonly occurs. The objective here is to optimize PMT therapy using induced pluripotent stem cell-derived MФs (iPS-MФs) in hPAP model mice. The central hypothesis is that iPS-MФs can be used to generate MФs that recapitulate the phenotypic and functional characteristics of alveolar MФs, permit a deeper exploration of hPAP pathogenesis, and serve as a source of gene-repaired MФs for PMT therapy of hPAP. The rationale, based on our preliminary data, is that the proposed research will establish the feasibility and lay the groundwork for development of a new personalized medicine approach for treating children with hPAP based on autologous PMT of gene-edited iPS-MФs. This hypothesis will be tested in the following three specific aims: 1) Recapitulation of phenotypically authentic alveolar macrophages from iPS cells; 2) An authentic cellular model of hPAP pathogenesis and its correction by genome editing; 3) Pulmonary macrophage transplantation of iPS-MФs as a novel cell therapy. The approach is innovative because it differs from current gene therapy approaches to generate gene-corrected primary MФs using semi-randomly integrating lentiviral vector. The proposed research will: 1) employ advanced iPS cell technology; 2) generate human hPAP-specific iPS cells and iPS-MФs to help elucidate disease pathogenesis; 3) repair mutant alleles with a non-viral, state-of-the-art synthetic endonuclease- mediated genome-editing system (e.g., CRISPR/Cas9); and 4) demonstrate the feasibility of using iPS-MФs for a novel organ-targeted cell and gene therapy (PMT) without a requirement for myeloablation or immunosuppression. The proposed research is significant because it will: 1) identify methods to accurately recapitulate the alveolar MФ phenotype from iPS cells, thereby providing a new general approach to study alveolar MФs in health and disease; 2) provide an authentic cellular model with which to study the pathogenesis of hPAP; 3) permit the optimization of a novel therapeutic strategy to simultaneously perform gene repair while minimizing safety concerns related to genotoxicity from insertional mutagenesis caused by viral vectors; and 4) demonstrate the feasibil... ## Key facts - **NIH application ID:** 9868322 - **Project number:** 5R01HL136721-04 - **Recipient organization:** CINCINNATI CHILDRENS HOSP MED CTR - **Principal Investigator:** Takuji Suzuki - **Activity code:** R01 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2020 - **Award amount:** $390,000 - **Award type:** 5 - **Project period:** 2017-02-06 → 2021-01-31 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/9868322 ## Citation > US National Institutes of Health, RePORTER application 9868322, Genome edited iPS cell-derived macrophages as a novel lung cell therapy (5R01HL136721-04). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9868322. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*